Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.
Adolescent
Adult
Anti-Anxiety Agents
/ therapeutic use
Antidepressive Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Anxiety
/ diagnosis
Cancer Survivors
/ psychology
Child
Cisplatin
/ adverse effects
Depression
/ diagnosis
Drug Prescriptions
/ statistics & numerical data
Hearing Loss
/ chemically induced
Humans
Kidney Diseases
/ chemically induced
Male
Middle Aged
Risk Factors
Self Report
/ statistics & numerical data
Testicular Neoplasms
/ drug therapy
Tinnitus
/ chemically induced
Young Adult
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
16
12
2020
revised:
24
02
2021
accepted:
06
04
2021
pubmed:
15
4
2021
medline:
27
1
2022
entrez:
14
4
2021
Statut:
ppublish
Résumé
This study examined sociodemographic factors, cisplatin-related adverse health outcomes (AHO), and cumulative burden of morbidity (CBM A total of 1,802 TCS who completed cisplatin-based chemotherapy ≥12 months previously completed questionnaires regarding sociodemographic features and cisplatin-related AHOs [hearing impairment, tinnitus, peripheral sensory neuropathy (PSN), and kidney disease]. A CBM A total of 151 TCS (8.4%) used medications for anxiety and/or depression. No cisplatin-related AHOs were reported by 511 (28.4%) participants, whereas 622 (34.5%), 334 (18.5%), 287 (15.9%), and 48 (2.7%), respectively, had very low, low, medium, and high CBM TCS with higher CBM Healthcare providers should encourage TCS to increase physical activity to improve both physical and mental health. Rehabilitation programs should assess work-related skills and provide career development counseling/training.
Sections du résumé
BACKGROUND
This study examined sociodemographic factors, cisplatin-related adverse health outcomes (AHO), and cumulative burden of morbidity (CBM
METHODS
A total of 1,802 TCS who completed cisplatin-based chemotherapy ≥12 months previously completed questionnaires regarding sociodemographic features and cisplatin-related AHOs [hearing impairment, tinnitus, peripheral sensory neuropathy (PSN), and kidney disease]. A CBM
RESULTS
A total of 151 TCS (8.4%) used medications for anxiety and/or depression. No cisplatin-related AHOs were reported by 511 (28.4%) participants, whereas 622 (34.5%), 334 (18.5%), 287 (15.9%), and 48 (2.7%), respectively, had very low, low, medium, and high CBM
CONCLUSIONS
TCS with higher CBM
IMPACT
Healthcare providers should encourage TCS to increase physical activity to improve both physical and mental health. Rehabilitation programs should assess work-related skills and provide career development counseling/training.
Identifiants
pubmed: 33849970
pii: 1055-9965.EPI-20-1762
doi: 10.1158/1055-9965.EPI-20-1762
pmc: PMC8172470
mid: NIHMS1695099
doi:
Substances chimiques
Anti-Anxiety Agents
0
Antidepressive Agents
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1129-1138Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157823
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
J Pain Symptom Manage. 2018 Jul;56(1):88-97
pubmed: 29524582
Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):293-302
pubmed: 24604103
Prev Chronic Dis. 2015 Mar 19;12:E38
pubmed: 25789499
Qual Life Res. 2006 Jun;15(5):791-800
pubmed: 16721639
Support Care Cancer. 2013 Dec;21(12):3307-13
pubmed: 23903798
J Oncol Pract. 2016 Aug;12(8):747-56
pubmed: 27382000
Support Care Cancer. 2013 Mar;21(3):757-63
pubmed: 22933132
Am J Med. 2010 Aug;123(8):711-8
pubmed: 20670725
Psychol Med. 2014 Apr;44(5):897-907
pubmed: 23778105
Cancer. 2013 Jun 1;119 Suppl 11:2151-9
pubmed: 23695927
Support Care Cancer. 2016 Sep;24(9):3907-14
pubmed: 27108264
J Psychosom Res. 2002 Feb;52(2):79-87
pubmed: 11832253
Eur Urol. 2007 Nov;52(5):1448-54
pubmed: 17544206
Patient Educ Couns. 2006 Dec;64(1-3):142-50
pubmed: 16480847
Psychooncology. 2019 Sep;28(9):1926-1933
pubmed: 31293046
J Clin Oncol. 2012 Oct 20;30(30):3752-63
pubmed: 23008318
J Clin Oncol. 2013 Jun 1;31(16):1961-9
pubmed: 23610114
J Clin Oncol. 2018 May 20;36(15):1505-1512
pubmed: 29617189
Ear Hear. 1982 May-Jun;3(3):128-34
pubmed: 7095321
Eur J Cancer. 2005 May;41(8):1135-9
pubmed: 15911236
Med Sci Sports Exerc. 1993 Jan;25(1):71-80
pubmed: 8292105
JNCI Cancer Spectr. 2020 Mar 20;4(4):pkaa022
pubmed: 32704617
Lancet Oncol. 2017 Jan;18(1):e39-e50
pubmed: 28049576
Int Rev Psychiatry. 2014 Feb;26(1):44-62
pubmed: 24716500
Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):645-661
pubmed: 29461592
Int J Epidemiol. 2014 Jun;43(3):962-70
pubmed: 24603316
Laryngoscope. 2011 Jul;121(7):1555-64
pubmed: 21671234
JAMA. 2015 Nov 3;314(17):1818-31
pubmed: 26529160
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
J Clin Oncol. 2014 May 20;32(15):1605-19
pubmed: 24733793
Urology. 2007 Apr;69(4):748-53
pubmed: 17445663
Cancers (Basel). 2017 May 20;9(5):
pubmed: 28531109
Int J Epidemiol. 1999 Feb;28(1):95-100
pubmed: 10195671
Ann Oncol. 2018 Jan 1;29(1):101-111
pubmed: 29272358
N Engl J Med. 2018 Dec 20;379(25):2438-2450
pubmed: 30575480
Otolaryngol Head Neck Surg. 2009 Mar;140(3):403-5
pubmed: 19248952
Am J Public Health. 1985 May;75(5):502-6
pubmed: 3985238
J Natl Cancer Inst. 2010 Aug 4;102(15):1114-30
pubmed: 20585105
J Clin Oncol. 2009 Dec 10;27(35):5993-9
pubmed: 19858403
J Clin Oncol. 2005 Apr 1;23(10):2389-95
pubmed: 15800331
J Clin Oncol. 2014 Jun 20;32(18):1941-67
pubmed: 24733808
Adv Urol. 2018 Feb 18;2018:8671832
pubmed: 29670654
Breast Cancer Res Treat. 2016 Sep;159(2):327-33
pubmed: 27510185
Arch Intern Med. 2003 Nov 10;163(20):2433-45
pubmed: 14609780
Int J Audiol. 2015;54(9):599-604
pubmed: 25766493
J Pain. 2011 Sep;12(9):964-73
pubmed: 21680251
Hear Res. 2016 Mar;333:255-265
pubmed: 26342399
Epidemiology. 1996 Jan;7(1):81-6
pubmed: 8664406
Lancet. 2013 Nov 9;382(9904):1600-7
pubmed: 23827090
J Chronic Dis. 1978;31(12):741-55
pubmed: 748370
J Clin Oncol. 2017 Apr 10;35(11):1211-1222
pubmed: 28240972
Curr Oncol. 2014 Aug;21(4):174-80
pubmed: 25089099
Contemp Clin Trials. 2018 Jan;64:179-187
pubmed: 29031492
J Pers Assess. 2008 Jul;90(4):348-55
pubmed: 18584443
N Engl J Med. 2018 Mar 29;378(13):1224-1231
pubmed: 29601255
JAMA. 2007 Jun 27;297(24):2705-15
pubmed: 17595271
Eur J Gastroenterol Hepatol. 2016 Jul;28(7):831-5
pubmed: 26928565
BMC Cancer. 2019 Oct 11;19(1):943
pubmed: 31604468
J Clin Oncol. 2017 Jan;35(1):78-85
pubmed: 28034075
Support Care Cancer. 2005 Aug;13(8):637-46
pubmed: 15756585
J Aging Health. 2017 Feb;29(1):172-184
pubmed: 26916793
Psychooncology. 2018 Apr;27(4):1129-1137
pubmed: 29171109